{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T21:08:38Z","timestamp":1768424918893,"version":"3.49.0"},"reference-count":10,"publisher":"Georg Thieme Verlag KG","issue":"03","license":[{"start":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T00:00:00Z","timestamp":1652832000000},"content-version":"vor","delay-in-days":1782,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["World J Nucl Med"],"published-print":{"date-parts":[[2017,7]]},"abstract":"<jats:p>The present study aimed at exploring the patient and imaging characteristics of primary neuroendocrine tumors (NETs) of rare sites who presented with metastatic and\/or advanced inoperable stages and therefore was considered for peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE. A retrospective analysis was undertaken of these patients focusing on the aforementioned aspects. All patients underwent dual-tracer molecular functional imaging with somatostatin receptor (SSTR)-based imaging (with either 99mTc-HYNIC-TOC or 68Ga-DOTATATE) and 18fluorine fludeoxyglucose positron emission tomography-computed tomography as the pretherapy assessment. Based on the qualitative uptake of tracer in SSTR imaging, the lesions were divided into four categories Grade 0\u2013III. The response was assessed post-PRRT by three parameters: (i) symptomatic response, (ii) biochemical response (serum tumor marker), and (iii) objective imaging response. The response profiles under each of these scales were assessed utilizing predefined criteria (detailed in methods). The overall response classification into partial response, stable disease, and progressive disease was done based on documentation of similar scale\/category of at least two parameters among the triple parametric assessment. A total of nine patients (7 males, 2 females; age range: 33\u201359 years) with rare site primary NET were found: The primary sites included ureter (n = 1), sacrococcygeal (n = 1), esophagus (n = 1), thymus (n = 3), and mediastinum (n = 3). Treatment response assessment was undertaken in eight patients who received more than 2 cycles of PRRT with 177Lu-DOTATATE. In this response assessment group (n = 8), the patients received 2\u20135 cycles and follow-up duration ranged from 5 to 48 months. Symptomatic responses and better quality of life were observed in 4\/8 (50%) patients, stable symptomatic disease in 3\/8 (37.5%), and progression in 1\/8 patients (12.5%). Biochemically, partial response was seen in 3\/8 (37.5%), stable values was seen in 3\/8 (37.5%), and progression of tumor marker was seen in 2\/8 (25%) patients. Morphologically, partial response was seen in 2\/8 (25%), stable disease in 5\/8 (62.5%), and progressive disease in 1\/8 (12.5%) patients. On overall assessment, 2\/8 patients (25%) demonstrated partial response, 4\/8 stable disease (50%), and 2\/8 progressive disease (25%) at the time of assessment. As per the RECIST 1.1, seven patients had stable disease and one patient had progressive disease. No specific correlation could be obtained between dual-tracer molecular imaging features and the response likely due to small population of the study group. Overall, there was evidence of excellent disease stabilization, and symptom palliation with 177Lu-DOTATATE PRRT was documented in these advanced or metastatic NETs of various rare sites.<\/jats:p>","DOI":"10.4103\/1450-1147.207283","type":"journal-article","created":{"date-parts":[[2017,5,30]],"date-time":"2017-05-30T06:23:33Z","timestamp":1496125413000},"page":"223-228","source":"Crossref","is-referenced-by-count":9,"title":["177Lu-DOTATATE peptide receptor radionuclide therapy in metastatic or advanced and inoperable primary neuroendocrine tumors of rare sites"],"prefix":"10.1055","volume":"16","author":[{"given":"Pradeep","family":"Thapa","sequence":"additional","affiliation":[{"name":"Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Hospital Annexe, Mumbai, Maharashtra"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rahul","family":"Parghane","sequence":"additional","affiliation":[{"name":"Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Hospital Annexe, Mumbai, Maharashtra"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandip","family":"Basu","sequence":"additional","affiliation":[{"name":"Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Hospital Annexe, Mumbai, Maharashtra"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2022,5,18]]},"reference":[{"key":"key-10.4103\/1450-1147.207283-1","first-page":"1","volume-title":"Neuroendocrine tumours","author":"Barakat","year":"2004","journal-title":"Endocr Relat Cancer"},{"key":"key-10.4103\/1450-1147.207283-2","first-page":"61","volume-title":"Gastroenteropancreatic neuroendocrine tumours","author":"Modlin","year":"2008","journal-title":"Lancet Oncol"},{"key":"key-10.4103\/1450-1147.207283-3","first-page":"1492","volume-title":"Dual tracer imaging approach in assessing tumor biology and heterogeneity in neuroendocrine tumors: Its correlation with tumor proliferation index and possible multifaceted implications for personalized clinical management decisions, with focus on PRRT","author":"Basu","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"key-10.4103\/1450-1147.207283-4","doi-asserted-by":"crossref","unstructured":"Thapa P, Ranade R, Ostwal V, Shrikhande SV, Goel M, Basu S. Performance of 177 Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics. Nucl Med Commun 2016. [Epub ahead of print].","DOI":"10.1097\/MNM.0000000000000547"},{"key":"key-10.4103\/1450-1147.207283-5","first-page":"1753","volume-title":"PRRT: Defining the paradigm shift to achieve standardization and individualization","author":"Bodei","year":"2014","journal-title":"J Nucl Med"},{"key":"key-10.4103\/1450-1147.207283-6","first-page":"766","volume-title":"Correlation and discordance of tumour proliferation index and molecular imaging characteristics and their implications for treatment decisions and outcome pertaining to peptide receptor radionuclide therapy in patients with advanced neuroendocrine tumour: Developing a personalized model","author":"Basu","year":"2015","journal-title":"Nucl Med Commun"},{"key":"key-10.4103\/1450-1147.207283-7","first-page":"83","volume-title":"Patient selection for personalized peptide receptor radionuclide therapy using Ga-68 somatostatin receptor PET\/CT","author":"Kulkarni","year":"2014","journal-title":"PET Clin"},{"key":"key-10.4103\/1450-1147.207283-8","first-page":"1927","volume-title":"A comparison of 68Ga-DOTATATE and 18F-FDG PET\/CT in pulmonary neuroendocrine tumors","author":"Kayani","year":"2009","journal-title":"J Nucl Med"},{"key":"key-10.4103\/1450-1147.207283-9","first-page":"1355","volume-title":"Scintigraphic imaging of body neuroendocrine tumors","author":"Intenzo","year":"2007","journal-title":"Radiographics"},{"key":"key-10.4103\/1450-1147.207283-10","first-page":"2447","volume-title":"Functional imaging of neuroendocrine tumors with combined PET\/CT using 68Ga-DOTATATE (DOTA-DPhe1, Tyr3-octreotate) and 18F-FDG","author":"Kayani","year":"2008","journal-title":"Cancer"}],"container-title":["World Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.4103\/1450-1147.207283.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T22:52:29Z","timestamp":1652914349000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.4103\/1450-1147.207283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":10,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2022,5,18]]},"published-print":{"date-parts":[[2017,7]]}},"URL":"https:\/\/doi.org\/10.4103\/1450-1147.207283","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["1450-1147","1607-3312"],"issn-type":[{"value":"1450-1147","type":"print"},{"value":"1607-3312","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7]]}}}